Replies to post #407391 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

Just so the implication is understood, Merck could lose the patent upon its expiration, but Keytruda’s useful life as a profitable drug in combination would be extended if Merck also holds the patent for DCVax. That’s why DCVax holds more value to Merck than perhaps any other BP.

It’s hard the make a logical business case for Merck NOT making a large offer. And as I’ve said a couple of times, Merck’s acquisition of Acceleron is irrelevant to any of this vis a vis an acquisition of NWBO.

New patent only applies to combination. The Keytruda patent in question expires in 7 years.

[Know-Fear]

No doubt. You and Poor Man have been noodling this and I have no real meat to add. Except the trial will perhaps be interesting/enlightening from a couple of possible prospectives. One being AE’s (adverse effects) could indicate the effectiveness of the combo and not necessarily be a “bad thing” for this trial. And two, being the possibility of the combo increasing the effectiveness of L to the overall spectrum of glioblastoma subtypes.